These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 31870373

  • 1. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
    Zezza M, Kosinski C, Mekoguem C, Marino L, Chtioui H, Pitteloud N, Lamine F.
    BMC Endocr Disord; 2019 Dec 23; 19(1):144. PubMed ID: 31870373
    [Abstract] [Full Text] [Related]

  • 2. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
    Omodaka T, Kiniwa Y, Sato Y, Suwa M, Sato M, Yamaguchi T, Sato A, Miyake T, Okuyama R.
    J Dermatol; 2018 Oct 23; 45(10):e289-e290. PubMed ID: 29667767
    [No Abstract] [Full Text] [Related]

  • 3. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 23; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 4. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
    Changizzadeh PN, Mukkamalla SKR, Armenio VA.
    J Immunother Cancer; 2017 Dec 19; 5(1):97. PubMed ID: 29254501
    [Abstract] [Full Text] [Related]

  • 5. Type 1 diabetes associated with immune checkpoint inhibitors for malignant melanoma: A case report and review of 8 cases.
    Ishiguro A, Ogata D, Ohashi K, Hiki K, Yamakawa K, Jinnai S, Tsutsui K, Takahashi A, Namikawa K, Yamazaki N.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30398. PubMed ID: 36107581
    [Abstract] [Full Text] [Related]

  • 6. Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer.
    Godwin JL, Jaggi S, Sirisena I, Sharda P, Rao AD, Mehra R, Veloski C.
    J Immunother Cancer; 2017 Sep 02; 5():40. PubMed ID: 28515940
    [Abstract] [Full Text] [Related]

  • 7. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN, Abushukair HM, Ababneh OE, Syaj SS, Al-Horani SS, Qarqash AA, Darabseh OA, Al-Sous MM, Al-Aomar SR, Ahmed YB, Haddad R, Al Qarqaz FA.
    Clin Transl Oncol; 2021 Sep 02; 23(9):1885-1904. PubMed ID: 33877531
    [Abstract] [Full Text] [Related]

  • 8. [Immune checkpoint inhibitors and endocrinological side effects].
    Jørgensen LB, Bastholt L, Yderstræde K.
    Ugeskr Laeger; 2017 Dec 04; 179(49):. PubMed ID: 29212592
    [Abstract] [Full Text] [Related]

  • 9. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
    Rodriguez EF, Lipson E, Suresh K, Cappelli LC, Monaco SE, Maleki Z.
    Hum Pathol; 2019 Sep 04; 91():69-76. PubMed ID: 31279873
    [Abstract] [Full Text] [Related]

  • 10. Case report: Strong GAD antibody positivity and type 1 diabetes-HLA-susceptible haplotype-DRB1*04:05-DQB1*04:01 in a Japanese patient with immune checkpoint inhibitor-induced type 1 diabetes.
    Yabuki S, Hirai H, Moriya C, Kusano Y, Hasegawa T.
    Front Endocrinol (Lausanne); 2024 Sep 04; 15():1407192. PubMed ID: 38841300
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, Hauschild A, Schilling B, Menzer C, Kieker F, Dippel E, Rösch A, Simon JC, Conrad B, Körner S, Windemuth-Kieselbach C, Schwarz L, Garbe C, Becker JC, Schadendorf D, Dermatologic Cooperative Oncology Group.
    Lancet; 2020 May 16; 395(10236):1558-1568. PubMed ID: 32416781
    [Abstract] [Full Text] [Related]

  • 12. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR, Nikita N, Banks J, Keith SW, Johnson JM, Wilson M, Lu-Yao G.
    JAMA Netw Open; 2021 Dec 01; 4(12):e2136823. PubMed ID: 34854905
    [Abstract] [Full Text] [Related]

  • 13. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
    Saibil SD, Bonilla L, Majeed H, Sotov V, Hogg D, Chappell MA, Cybulsky M, Butler MO.
    Curr Oncol; 2019 Jun 01; 26(3):e418-e421. PubMed ID: 31285688
    [Abstract] [Full Text] [Related]

  • 14. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK, Hall S, Green C, Van Hazel G, Spagnolo D, Cheah CY.
    Eur J Cancer; 2019 Jul 01; 115():84-87. PubMed ID: 31129384
    [No Abstract] [Full Text] [Related]

  • 15. Fulminant Type 1 Diabetes Mellitus Developed about Half a Year after Discontinuation of Immune Checkpoint Inhibitor Combination Therapy with Nivolumab and Ipilimumab: A Case Report.
    Yaura K, Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2021 Aug 01; 254(4):253-256. PubMed ID: 34373422
    [Abstract] [Full Text] [Related]

  • 16. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
    Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD.
    Lancet Oncol; 2018 Nov 01; 19(11):1480-1492. PubMed ID: 30361170
    [Abstract] [Full Text] [Related]

  • 17. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E, Beckermann KE, Ozgun A, Kelly C, McKean M, McQuade J, Thompson MA, Puzanov I, Greer JP, Rapisuwon S, Postow M, Davies MA, Eroglu Z, Johnson D.
    J Immunother Cancer; 2017 Nov 01; 5():8. PubMed ID: 28239462
    [Abstract] [Full Text] [Related]

  • 18. Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an update.
    Kähler KC, Hassel JC, Heinzerling L, Loquai C, Thoms KM, Ugurel S, Zimmer L, Gutzmer R, committee on “Cutaneous Adverse Events“ of the German Working Group for Dermatological Oncology (Arbeitsgemeinschaft Dermatologische Onkologie, ADO).
    J Dtsch Dermatol Ges; 2020 Jun 01; 18(6):582-609. PubMed ID: 32489011
    [Abstract] [Full Text] [Related]

  • 19. Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.
    Chorti E, Kanaki T, Zimmer L, Hadaschik E, Ugurel S, Gratsias E, Roesch A, Bonella F, Wessendorf TE, Wälscher J, Theegarten D, Schadendorf D, Livingstone E.
    Eur J Cancer; 2020 May 01; 131():18-26. PubMed ID: 32248071
    [Abstract] [Full Text] [Related]

  • 20. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
    Rozeman EA, Menzies AM, van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, Broeks A, van Thienen JV, Guminski AD, Acosta AT, Ter Meulen S, Koenen AM, Bosch LJW, Shannon K, Pronk LM, Gonzalez M, Ch'ng S, Grijpink-Ongering LG, Stretch J, Heijmink S, van Tinteren H, Haanen JBAG, Nieweg OE, Klop WMC, Zuur CL, Saw RPM, van Houdt WJ, Peeper DS, Spillane AJ, Hansson J, Schumacher TN, Long GV, Blank CU.
    Lancet Oncol; 2019 Jul 01; 20(7):948-960. PubMed ID: 31160251
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.